Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review
- 8 April 2026
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (8) , 1816-1819
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The Impact of Tirabrutinib Monotherapy for the Treatment of Bing‐Neel Syndrome: A Multicenter Retrospective StudyAmerican Journal of Hematology, 2025
- Bing-Neel Syndrome - A Case Series of 46 Patients from the United KingdomBlood Advances, 2025
- Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel SyndromeAmerican Journal of Hematology, 2025
- Zanubrutinib in Bing Neel syndrome: efficacy and tolerabilityLeukemia, 2025
- Zanubrutinib for the treatment of Bing–Neel syndromeBritish Journal of Haematology, 2025
- Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemiaBlood Advances, 2024
- Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSeminars in Hematology, 2023
- Identification and functional characterization of new missense SNPs in the coding region of the TP53 geneCell Death & Differentiation, 2020
- Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyBlood, 2019
- The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemiaCancer Chemotherapy and Pharmacology, 2015